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Abstract
Background: It has been suggested that an extensive contractile reserve identified recognised by
means of dobutamine stress echocardiography may predict a better prognosis in patients with
severe left ventricular dysfunction at rest. However, the clinical use of dobutamine stress
echocardiography may be limited in patients with chronic heart failure by the substantial proportion
of such patients treated with beta-blockers, since the inotropic response to adrenergic stimulation
is known to be attenuated in patients receiving beta-adrenoceptor blockers. Enoximone is a
positive inotropic agent that inhibits cyclic adenosine monophosphate-specific phosphosdiesterase.
We therefore tested the hypothesis that enoximone may be an alternative to dobutamine in
evaluating left ventricular contractile reserve in patients with systolic dysfunction on chronic beta-
blocker therapy.
Methods: We studied 26 patients (21 males and five females) with a mean age of 58 ± 10 years:
11 were not receiving beta-blockers (noBB group); 15 were receiving carvedilol at a mean dose of
34 mg/day (BB group). Dobutamine was infused at doses of 5 and 10 micrograms/kg/min, and
enoximone at a dose of 1.5 mg/kg.
Results: The ejection fraction in the noBB group increased by 9% with dobutamine and 8.73% with
enoximone (p = 0.86); in the BB group, it increased by 6% with dobutamine and 8.94% with
enoximone (p = 0.03). Regional peak systolic velocities were evaluated by means of tissue Doppler
imaging in four basal and four medium level segments. In the noBB group, they increased more with
dobutamine than with enoximone in three of the eight segments; no significant differences were
found in the BB group. Dobutamine induced non-sustained ventricular tachycardia in three patients
and supraventricular tachycardia in one, whereas enoximone did not induce any repetitive
arrhythmias.
Conclusions: Enoximone might be preferable to low-dose dobutamine for evaluating left
ventricular contractile reserve in chronically beta-blocked heart failure patients as it is slightly more
potent and has a better safety profile.
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The human myocardium is a predominantly beta-adren-
ergic organ in which receptor density and sensitivity deter-
mine the response to adrenergic stimulation. In patients
with severe left ventricular systolic dysfunction, the
responsiveness of the beta-adrenergic receptor is dimin-
ished as a result of the decreased density of beta-1 recep-
tors and the decreased sensitivity of beta-2 receptors [1].
Rapidly growing published data suggest that the presence
of a an extensive contractile reserve recognised by means
of dobutamine stress echocardiography may predict a bet-
ter prognosis in patients with severe left ventricular dys-
function at rest. However, the clinical use of dobutamine
stress echocardiography in patients with chronic heart
failure may be limited by the substantial proportion
receiving beta-blocker therapy since the inotropic
response to adrenergic stimulation is known to be attenu-
ated in patients receiving beta-adrenoceptor blockers.
Experimental and clinical studies have shown that enoxi-
mone has a positive inotropic effect that is not accompa-
nied by a significant increase in myocardial oxygen
consumption. It increases coronary blood flow and
reduces vascular resistances. The inotropic effect of both
enoximone and dobutamine is obtained via the same
final biochemical pathway (an increase in intracellular
cyclic adenosine monophospate) but by means of differ-
ent mechanisms: enoximone acts distally to the beta-
adrenoceptor, and binds directly and selectively to the
intracellular enzyme phosphodiesterase III that specifi-
cally degrades cardiac cyclic adenosine monophosphate.
Its effectiveness is therefore not impaired by beta-adreno-
ceptor down-regulation or the administration of beta-
blocking agents [2]. A number of studies have previously
demonstrated the feasibility and safety of enoximone
stimulation in evaluating myocardial viability in patients
with ischemic heart disease [3,4], and so the aim of this
prospective study was to compare the feasibility of enoxi-
mone and conventional low-dose dobutamine echocardi-
ography in assessing myocardial contractile reserve in
chronic heart failure patients. We also evaluated regional
myocardial function as recent studies have suggested that
tissue Doppler is more accurate in identifying myocardial




We selected patients with chronic heart failure due to
advanced systolic dysfunction who were referred to our
department for heart failure management or heart trans-
plant screening. The inclusion criteria were an ejection
fraction of ≤35%, sinus rhythm and a clinically stable con-
dition during the previous three months. The exclusion
criteria were myocardial infarction or unstable angina in
the previous six months, significant valvular disease, and
sustained or non-sustained ventricular tachycardia on
recent electrocardiographic Holter monitoring.
We enrolled 26 patients (21 male and five females) with a
mean age of 58 ± 10 years; two patients were in New York
Heart Association functional class I, 20 in class II and four
in class III. The etiology of heart failure was idiopathic in
13 patients, ischemic in six, hypertensive in three, and
unknown in four. Eleven patients were not receiving beta-
blockers (noBB group); the remaining 15 were receiving
carvedilol at a mean dose of 34 mg/day (BB group). The
baseline characteristics of the patients were similar in the
two groups (Table 1).
Study protocol
Each patient underwent dobutamine and enoximone
stress echocardiography on two consecutive days; the test
sequence was random. All of the patients gave their writ-
ten informed consent. Dobutamine echocardiography
was performed using a low-dose protocol with incremen-
tal doses of 5 and 10 µg/kg/min at 10-minute intervals;
the images were taken at baseline and at the end of each
infusion step. Enoximone echocardiography was per-
formed using a dose of 1.5 mg/kg, which was chosen on
the basis of the results of a previous study showing that it
had 87% sensitivity for predicting functional recovery
after revascularisation [4]. The enoximone was diluted
with saline to a concentration of 2.35 mg/mL in order to
avoid a peripheral venous burning sensation, and infused
over ten minutes. The echocardiographic images were
recorded at baseline and two minutes after the infusion.
Changes in blood pressure (BP delta) and in heart rate (HR delta) in beta-blocked patients, uring enoximone and dob-utamine stress testFigur  1
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lead electrocardiogram was monitored continuously and
recorded before and after each step of the test. Blood pres-
sure was measured at 5-minute intervals and at the end of
the test using a cuff sphygmomanometer. Two-dimen-
sional images were obtained from the apical 4- and 2-
chamber views and stored on hard disk for the off-line cal-
culation of left ventricular end-diastolic and end-systolic
volumes and ejection fraction. Colour tissue Doppler
images of the left ventricle in 4- and 2-chamber views were
also stored on hard disk for later analysis. All of the stud-
ies were performed using a Vingmed System Five ultra-
sound system. The generated tissue Doppler cineloops
were stored on the Vingmed Echopac System hard disk
and used for the off-line determination of mean regional
systolic velocities. The off-line analyses were made by a
physician blinded to the test sequence.
Statistical analysis
The data are shown as mean values ± SD for continuous
variables, and absolute or relative frequencies for categor-
ical variables. The mean group values were compared
using the unpaired t test, and the test results within each
group by means of the paired t test. A 2-sided p value of
<0.05 was considered statistically significant. The compu-
tations were made using Stata 7 software (Stata Corp, Col-
lege Station, TX).
Results
Blood pressure, heart rate and arrhythmias (Figures 1 and 
2) (Table 2)
Blood pressure increased more with dobutamine than
with enoximone in both groups; in the patients not receiv-
ing beta-blocker therapy, it actually decreased with enoxi-
mone. Symptomatic hypotension occurred in three
Table 1: Baseline characteristics of the two groups of patients
noBB Group BB Group p value
BP (mmHg) 114 ± 16 116 ± 12 0.76
HR (beats/min) 72 ± 8 70 ± 10 0.45
EDV (ml) 257 ± 88 296 ± 87 0.28
ESV (ml) 174 ± 73 219 ± 82 0.16
EF (%) 33.3 ± 6 27.7 ± 7 0.04
bsv (cm/s) 3.18 ± 1.79 4.12 ± 1.51 0.17
msv (cm/s) 2.25 ± 2.08 4.08 ± 2.01 0.03
blv (cm/s) 3.64 ± 1.58 2.96 ± 1.87 0.33
mlv (cm/s) 2.92 ± 1.88 2.35 ± 1.43 0.41
biv (cm/s) 3.77 ± 1.85 3.55 ± 1.45 0.75
miv (cm/s) 3.34 ± 2.58 3.10 ± 3.59 0.78
bav (cm/s) 3.74 ± 1.62 3.74 ± 2.41 1.00
mav (cm/s) 2.76 ± 1.74 2.41 ± 2.39 0.66
BP = blood pressure; HR = heart rate; EDV = end-diastolic volume; ESV = end-systolic volume; EF = left ventricular ejection fraction.; bsv = basal 
septum velocity; msv = medium septum velocity; blv = basal lateral velocity, mlv = medium lateral velocity, biv = basal inferior velocity, miv = 
medium inferior velocity, bav = basal anterior velocity, mav = medium anterior velocity.
Table 2: Changes in heart rate and blood pressure in the two groups
noBB Group
Dobutamine Enoximone p
∆ BP (mmHg) 20 ± 18 -7.5 ± 12 0.0025
∆ HR (beats/min) 21 ± 16 12 ± 8 0.1742
BB Group
Dobutamine Enoximone p
∆ BP (mmHg) 25 ± 24 7 ± 13 0.0222
∆ HR (beats/min) 5 ± 15 8 ± 9 0.5402
Abbreviations as in Table 1.Page 3 of 6
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90 mmHg) and rapidly recovered spontaneously (two
cases) or after liquid infusion (one case). There was no sig-
nificant difference in heart rate response between the two
agents. Dobutamine induced non-sustained ventricular
tachycardia in three patients and supraventricular tachy-
cardia in one, whereas no repetitive arrhythmias were
observed during the enoximone test.
Global left ventricular function (Tables 3 and 4)
Although the inotropic agents decreased end-diastolic
volume to a similar extent in both groups, enoximone
decreased end-systolic volume significantly more in the
patients receiving beta-blocker therapy. Consequently, in
the noBB group, the ejection fraction increased by 9%
with dobutamine and 8.73% with enoximone (p = 0.86)
and, in the BB group, it increased by 6% with dobutamine
and 8.94% with enoximone (p = 0.03).
Regional myocardial function (Tables 3 and 4)
In the noBB group, tissue velocities increased more with
dobutamine than with enoximone in three of the eight
segments analysed: the basal and medium anterior seg-
ments, and the medium lateral segment. There were no
statistically significant differences in regional tissue veloc-
ities in the BB group.
Discussion
The evaluation of left ventricular contractile reserve seems
to be a promising new tool for the prognostic stratifica-
tion of patients with heart failure. We tested the hypothe-
sis that enoximone may have a better safety profile than
dobutamine, and that it may be a better inotropic
stimulus for patients on chronic beta-blocker therapy and
therefore applicable to a larger proportion of patients with
heart failure. The results indicate that enoximone does not
induce repetitive arrhythmias and that it is slightly more
Table 3: Global and regional responses to inotropic stimulation in the noBB Group
Dobutamine Enoximone p
∆ EDV (ml) -23 ± 20 -18 ± 25 0.5688
∆ ESV (ml) -35 ± 24 -30 ± 13 0.4791
∆ EF (units) 9.0 ± 5 8.7 ± 4 0.8583
∆ bsv (cm/s) 1.75 ± 2.13 1.26 ± 1.72 0.6377
∆ msv (cm/s) 1.11 ± 2.67 1.54 ± 1.76 0.6340
∆ blv (cm/s) 2.98 ± 3.31 1.46 ± 2.01 0.1780
∆ mlv (cm/s) 2.48 ± 1.84 0.97 ± 2.09 0.0320
∆ biv (cm/s) 2.17 ± 2.21 0.92 ± 0.79 0.0561
∆ miv (cm/s) 1.31 ± 3.34 0.84 ± 0.75 0.6420
∆ bav (cm/s) 3.81 ± 2.53 0.10 ± 3.17 0.0174
∆ mav (cm/s) 2.80 ± 2.53 0.0 3 ± 2.17 0.0170
∆ = difference between stress and baseline values; other abbreviations as in Table 1.
Table 4: Global and regional responses to inotropic stimulation in the BB Group
Dobutamine Enoximone p value
∆ EDV (ml) -5 ± 22 -12 ± 20 0.1508
∆ ESV (ml) -20 ± 26 -33 ± 17 0.0136
∆ EF (units) 6 ± 6 8.9 ± 6 0.0323
∆ bsv (cm/s) 1.30 ± 1.17 1.12 ± 1.44 0.7709
∆ msv (cm/s) 1.20 ± 1.24 0.38 ± 1.2 0.0682
∆ blv (cm/s) 0.09 ± 4.99 1.50 ± 1.09 0.3171
∆ mlv (cm/s) 0.17 ± 3.28 1.85 ± 1.65 0.1876
∆ biv (cm/s) 1.81 ± 2.1 1.07 ± 1.74 0.1759
∆ miv (cm/s) 1.56 ± 1.58 1.15 ± 1.18 0.3251
∆ bav (cm/s) 0.65 ± 2.46 1.61 ± 1.38 0.1954
∆ mav (cm/s) 0.06 ± 2.62 1.15 ± 1.66 0.2862
∆ = difference between stress and baseline values; other abbreviations as in Table 1.Page 4 of 6
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beta-blocker therapy.
Dobutamine stress echocardiography for evaluating 
inotropic reserve
It has been found that an extensive contractile reserve
identified by dobutamine stress-echocardiography is asso-
ciated with better survival [8–11] and predicts recovery of
left ventricular function in patients with recent onset idio-
pathic dilated cardiomyopathy [12–15]. More, in patients
with ischemic heart disease and left ventricular dysfunc-
tion, the myocardial viability recognised by low-dose
dobutamine echocardiography is associated with better
survival [16]. However, few of these studies evaluated
patients on chronic beta-blocker therapy. The great major-
ity of heart failure patients currently receive chronic beta-
blocker therapy, which is known to interfere with the
response to dobutamine: a recently published study has
demonstrated that long-term carvedilol therapy inhibits
the hemodynamic response to dobutamine, whereas the
response to enoximone is not significantly changed [17].
Moreover, the previous studies did not use the same dob-
utamine stress echocardiography protocol, with some
authors using high doses of dobutamine in order to reveal
myocardial contractile reserve [10]; however, the use of
high dobutamine doses may lead to a high arrhythmic
risk in patients with advanced left ventricular dysfunction.
Enoximone stress echocardiography for evaluating 
myocardial viability
A number of studies have attempted to identify viable
myocardium in patients with ischemic heart disease, and
it has been shown that it can be identified after a myocar-
dial infarction as precisely and safely by means of an
enoximone bolus as by means of dobutamine infusion;
the sensitivity, specificity and overall accuracy of enoxi-
mone stress echocardiography in predicting reversible
dysfunction after myocardial infarction were respectively
93%, 85% and 88% [3]. Another study used enoximone
echocardiography to predict functional recovery after
myocardial revascularisation, and found that it was more
sensitive and had a greater negative predictive value than
dobutamine, and also induced fewer hemodynamic alter-
ations [4]. Finally, enoximone has been combined with
very low-dose dobutamine in order to detect myocardial
viability in the infarcted myocardium of patients with
severe heart failure and life-threatening arrhythmias [18].
Enoximone stress echocardiography for evaluating left 
ventricular contractile reserve
In our study, the ejection fraction increased to a similar
extent in the patients not receiving beta-blockers after
both low-dose dobutamine and enoximone but, in the
patients on chronic beta-blocker therapy, it not only
increased more with enoximone, but also (and interest-
ingly) to the same extent as in the non-treated patients.
These results are consistent with the theoretical
background and the results of studies of post-infarction
patients [3,4].
We also measured regional myocardial velocities by
means of tissue Doppler echocardiography because recent
studies have suggested that tissue Doppler data can accu-
rately identify myocardial viability or ischemia [5–7].
However, the information gathered by evaluating regional
myocardial velocities in our patients could not replace the
assessment of global systolic function. In the noBB group,
tissue velocities increased more with dobutamine in three
of the eight analysed segments (the basal and medium
anterior segments and the medium lateral segment)
whereas, in the BB group, no significant difference was
observed in any segment. It is possible that the low base-
line tissue velocities due to advanced left ventricular dys-
function, and the less potent inotropic stimulus (which
was used to assess the presence of contractile reserve
rather than to elicit the occurrence of ischemia), may
explain this difference in comparison with previous
studies.
In terms of safety, enoximone did not induce any repeti-
tive arrhythmias, which is very important when studying
patients with left ventricular dysfunction who are, by def-
inition, at increased arrhythmic risk. The few cases of mild
hypotension occurring with enoximone rapidly resolved.
One limitation of the present study is that we only
enrolled patients with a NYHA functional class of no
Changes in blood pressure (BP delta) and in heart rate (HR delta) in non beta-blocked patients, during enoximon  and obutami e stress t stFig r  2
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more than III. We did not study more advanced patients
and we cannot predict the potential adverse effects of the
two inotropic agents in such subjects. We also cannot pre-
dict the safety profile of enoximone in patients with sus-
tained ventricular arrhythmias.
Conclusions
Enoximone proved to be as useful as low-dose dob-
utamine in evaluating left ventricular contractile reserve in
chronically beta-blocked heart failure patients, but its bet-
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